8 May 2026
When post supply rebates do (and do not) reduce VAT
Boehringer Ingelheim (BI) manufactures and sells medicines in the UK. Most supplies were made at the standard rate to wholesalers and pharmacies, who ultimately supplied medicines to NHS patients. Under the NHS VPAS scheme, BI was required to make periodic payments to the Department of Health and Social Care (DHSC), calculated by reference to overall NHS expenditure on branded medicines. BI treated those payments as retrospective price rebates and claimed overpaid output VAT under Article 90 of EU Principal VAT Directive.
BI argued that payments by BI to DHSC reduced the consideration for its taxable supplies of medicines. The First tier Tribunal agreed, finding a sufficient link between the payments and BI’s earlier taxable supplies.
The Upper Tribunal disagreed, and held that Article 90 relief is available only where a rebate directly reduces the consideration for identifiable supplies, and where there is a clear reciprocal link between the payment and what the supplier receives. The Tribunal found that DHSC was acting as a public funder rather than a customer, and that payments based on aggregate NHS spend were too remote to have a direct link to any particular supply of Medicines or to the supply of Medicines generally into final consumption.
Relief was allowed only where BI supplied medicines directly to DHSC, which in those cases was the final consumer and contractual counterparty
Conclusion / key takeaway / recommendation
The decision reaffirms that VAT relief for post‑supply rebates hinges on analysis of commercial and contractual detail. Relief remains possible, but only where a payment genuinely reduces the price of identifiable supplies and has a direct link to the consideration paid by, or on behalf of, the final consumer. Careful structuring and review are essential before assuming VAT adjustments apply.
